A glycoprotein E gene-deleted bovine herpesvirus 1 as a candidate vaccine strain

M. Weiss¹, M.C.S. Brum², D. Anziliero¹, R. Weiblen¹ and E.F. Flores¹

¹Setor de Virologia, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria, Santa Maria, RS, Brasil
²Laboratório de Virologia, Curso de Medicina Veterinária, Universidade Federal do Pampa, Uruguaiana, RS, Brasil

Abstract

A bovine herpesvirus 1 (BoHV-1) defective in glycoprotein E (gE) was constructed from a Brazilian genital BoHV-1 isolate, by replacing the full gE coding region with the green fluorescent protein (GFP) gene for selection. Upon co-transfection of MDBK cells with genomic viral DNA plus the GFP-bearing gE-deletion plasmid, three fluorescent recombinant clones were obtained out of approximately 5000 viral plaques. Deletion of the gE gene and the presence of the GFP marker in the genome of recombinant viruses were confirmed by PCR. Despite forming smaller plaques, the BoHV-1ΔgE recombinants replicated in MDBK cells with similar kinetics and to similar titers to that of the parental virus (SV56/90), demonstrating that the gE deletion had no deleterious effects on replication efficacy in vitro. Thirteen calves inoculated intramuscularly with BoHV-1ΔgE developed virus neutralizing antibodies at day 42 post-infection (titers from 2 to 16), demonstrating the ability of the recombinant to replicate and to induce a serological response in vivo. Furthermore, the serological response induced by recombinant BoHV-1ΔgE could be differentiated from that induced by wild-type BoHV-1 by the use of an anti-gE antibody ELISA kit. Taken together, these results indicated the potential application of recombinant BoHV-1 ΔgE in vaccine formulations to prevent the losses caused by BoHV-1 infections while allowing for differentiation of vaccinated from naturally infected animals.

Key words: Cattle pathogen; Immunization; Control; Differential vaccine

Introduction

Bovine herpesvirus 1 (BoHV-1) is an important pathogen of cattle, associated with a variety of clinical manifestations including respiratory disease (infectious bovine rhinotracheitis), genital disorders (infectious pustular vulvovaginitis or infectious pustular balanoposthitis), transient infertility and abortions in cattle (1). BoHV-1 is an enveloped DNA virus belonging to the family Herpesviridae, subfamily Alphaherpesvirinae, genus Varicellovirus (2). BoHV-1 infection is widely distributed around the world, with the exception of a few European countries that have eradicated it. A number of studies have demonstrated the wide distribution of BoHV-1 infection and disease in Brazil (3,4). Like other alphaherpesviruses, BoHV-1 establishes lifelong latent infection in sensory nerve ganglia following acute infection, from which it can be periodically reactivated and transmitted. Thus, latency and reactivation provide adequate means for virus perpetuation in nature (5).

Vaccination has been largely used as one of the strategies to prevent and to reduce the losses associated with BoHV-1 infection (6). Traditional vaccines usually contain attenuated or whole inactivated virus and induce a serological response undistinguishable from that induced by natural infection. The inability to differentiate vaccinated from naturally infected animals impairs control/eradication efforts based on the identification and segregation and/or culling of seropositive animals (7). In this regard, gene-deleted vaccines that allow for serological differentiation - also called differentiating infected from vaccinated animals (DIVA) vaccines - have arisen as alternatives to traditional vaccines (8). Such vaccines have long been used in several European and North American countries (2). In particular, this strategy fits well for herds and/or regions undertaking control/eradication efforts (8). A similar approach was successfully employed to eradicate pseudorabies virus in several countries (9).

Correspondence: E.F. Flores: <eduardofurtadoflores@gmail.com>.

The current address of D. Anziliero is Escola de Medicina, Faculdade Meridional, Passo Fundo, RS, Brasil.

Received August 4, 2014. Accepted April 2, 2015. First published online July 21, 2015.
The BoHV-1 genome is approximately 138-kb long and encodes around 70 products, of which 10 are envelope glycoproteins. Envelope glycoproteins play important roles in viral biology, pathogenesis and constitute major targets for the host immune system (10). Interestingly, some envelope glycoproteins are non-essential for virus replication in cell culture and in vivo and, as such, have been deleted for the production of attenuated and/or antigenically marked vaccine strains (11). The envelope glycoprotein E (gE) has been the target for deletion in the production of antigenically marked vaccines for several herpesviruses such as BoHV-1 (7,12,13) and BoHV-5 (14,15). The choice of gE has relied upon the following reasons: i) gE is non-essential for virus replication in vitro and in vivo and its deletion does not usually significantly reduce the efficiency of virus replication in vivo (16); ii) gE deletion usually contributes to viral attenuation (11); iii) gE deletion does not affect viral immunogenicity (7,11,13), and iv) gE is fairly immunogenic, a desirable property for an antigenic marker (12). For these reasons, most BoHV-1 marker vaccines available worldwide contain recombinant gE-negative viral strains (7,17,18).

Efforts to produce commercially viable BoHV-1 marker vaccines have long been reported in Brazil (19,20). A gE-negative BoHV-1 strain was constructed and evaluated in terms of safety, immunogenicity and potential serological differentiation (21,22). More recently, a gE-negative BoHV-1 strain was constructed and proposed as a candidate vaccine strain (14). Unfortunately, no BoHV marker strain was constructed and proposed as a candidate thymidine kinase double deletion BoHV-5 recombinant marker; a desirable property for an antigenic marker (12).

**Material and Methods**

**Virus strain, cells and plasmid vectors**

The Brazilian BoHV-1 strain SV56/90, isolated from preputial swabs and semen of bulls with balanoposthitis (23), was used as the parental virus to construct recombinant viruses. Madin Darby bovine kidney cells (MDBK, ATCC, CCL-22) maintained in Eagle’s Minimum Essential Medium (HiMedia Laboratories, India), supplemented with 10% inactivated and γ-irradiated fetal bovine serum (Nutricell, Brazil), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen, USA) were used in all procedures.

The plasmid vectors used in the construction/recombination procedures included: i) a deletion plasmid (pBoHV-1ΔgE) to introduce the gE deletion in to the BoHV-1 genome and add the green fluorescent protein (GFP) marker; ii) a plasmid expressing the bovine immediate-early gene ICP0 (bICP0), used as transactivator of the initiation of the transcription of the immediate early genes of the BoHV-1 genome (24), and iii) a plasmid expressing the GFP gene used for construction of the pBoHV-1ΔgE plasmid. The bICP0 plasmid was kindly provided by Dr. Clinton Jones (University of Nebraska at Lincoln, USA).

**Construction of BoHV-1 gE deletion plasmid**

The deletion plasmid pBoHV-1ΔgE was constructed by replacing the entire gE open reading frame (Figure 1A) with the GFP gene as a marker for selection. To construct this plasmid, the upstream and downstream sequences of the gE gene (gl and Us9, respectively) were amplified by PCR, using Platinum® Taq DNA Polymerase High Fidelity (Invitrogen) and cloned into pBlueScriptII KS (+) vector (Stratagene, USA). The gE upstream sequence was PCR amplified using a pair of primers (gl FW: 5'-CACAG GATCCGTTTGTACACAGCTTCGG-3' and gl RW: 5'-CACAGAAATTCGCCAAATGCCTTTTGCG-3'), resulting in a product of 933 bases pairs (bp) that incorporates BamHI/EcoRI sites at the 5' and 3' ends, respectively. The gE downstream sequence was PCR amplified using a pair of primers (Us9 FW: 5'-CACAGAGCTGCTGCTGCTGCGGAA-3' and Us9 RW: 5'-CACAGCTGCTGCTGCGGAA-3') resulting in a product of 888 bp that incorporates HindIII/KpnI sites at the 5' and 3' ends, respectively (Figure 1B). To introduce the GFP gene between the gl and Us9 fragments, a PCR reaction using

---

**Figure 1.** Strategy for the construction of the gE deletion plasmid. A, Schematic organization of the BoHV-1 genome and their unique long (UL) and short (US) regions and repeats (internal, IR, and terminal, TR). B, Amplified view of the organization of the BoHV-1 genome within the US region corresponding to the gE gene. Arrows show the primers used for amplifying the gE flanking regions. C, Schematic organization of the deletion plasmid containing the regions for homologous recombination and the restriction endonuclease sites used in the cloning strategy.
a pair of primers (GFP insertion FW 5'-CACAGAATTCT 
GACCTGAGCCCTGATT-3' and GFP insertion RW 
5'-CAACAAAGCTTCATCGACTTG TACTT-3') was performed 
using the pEGFP-C1 plasmid (Clontech Lab, USA) 
as template, resulting in a product of 1,856 bp that 
incorporates EcoRI and HindIII sites at the ends. 
PCR products were digested with the respective enzymes 
and cloned between the gl and Us9 fragments. The deletion 
plasmid (pBoHV-1ΔgE) contained the GFP gene replacing 
the gE gene (Figure 1C).

DNA extraction and transfection

Extraction of genomic viral DNA was performed 
especially as described (13). Briefly, MDBK cells were inoculated 
with SV56/90 strain at a multiplicity of infection of 0.1. When 
the cytopathic effect reached around 90% of the monolayer, 
the supernatant was collected and clarified by low-speed 
centrifugation (1,500 g for 30 min). The supernatant was 
then subjected to ultracentrifugation in a 30% sucrose 
cushion for 2 h at 112,500 g. The resulting pellet was 
resuspended in 1 x TE (10 mM Tris-HCl, 5 mM EDTA, pH 8.0) 
and pre-digested in 1% SDS and RNAase A (Invitrogen) 
for 30 min at room temperature. The digestion was 
completed by adding 500 μg/mL of protease K (Sigma- 
Aldrich, USA) and performing a new incubation at 56°C for 
30 min. Following digestion, viral DNA was extracted with 
phenol:chloroform:isoamyl-alcohol (25:24:1), followed by 
ethanol precipitation according to standard protocols.

DNA of pBoHV-1ΔgE and the BoHV-1 biCP0 gene 
was extracted using the Qiagen Plasmid Midi Kit (Qiagen, 
USA). Full length viral DNA and plasmids were co- 
transfected into MDBK cells using Lipopectamine reagent 
(PolyFect Transfection Reagent, Qiagen) and Opti-Mini- 
umum Essential Medium I (Gibco-BRL, USA) as part of the 
lipectamine protocol (13,14).

Generation and selection of recombinant viruses

To generate the BoHV-1 gE deleted virus, the 
linearized pBoHV-1ΔgE plasmid, the full length wild type 
virus SV56/90 DNA and the biCP0 plasmid were co- 
transfected into MDBK cells, using Lipopectamine reagent 
(Invitrogen) as described previously (13). After 48-72 h, 
cell cultures showing evident cytopathic effects were 
freeze-thawed, centrifuged at low speed (1,500 g for 
15 min) and the supernatants were subjected to plaque 
plurification in MDBK monolayers using a low melting 
agarose overlay. After 72 h, the plates were examined 
under UV light to search for fluorescent plaques. 
Fluorescent plaques were picked and amplified in MDBK 
cells for subsequent characterization.

PCR confirmation of gE deletion

To confirm deletion of the gE gene in the fluorescent 
viruses recovered from transfected cultures, a PCR 
reaction using a pair of primers that amplify the deleted 
region was performed. Total DNA from mock-infected 
MDBK cells, MDBK cells infected with the parental virus 
(BoHV-1 SV56/90), or MDBK cells infected with viruses 
amplified from fluorescent plaques was extracted using 
proteinase K digestion and phenol/chloroform extraction 
as described in the section DNA extraction and transfection. 
The PCR reaction was carried out in a 50-μL volume 
containing 1 µL PCR buffer, 0.2 mM dNTPs, 0.4 μM of 
each primer (BoHV-1 gE FW: 5'-GCCGACCATCGACTGG 
TACCTT-3' and BoHV-1 gE RW: 5'-GCACAAAGACG 
TAAAGCCCG-3'), 1.25 U of Taq DNA polymerase (Invitrogen), 
1.5 mM of MgCl2, 10% DMSO and 0.1 μg of DNA as 
template. The PCR conditions consisted of initial dena- 
turation at 95°C for 10 min; followed by 40 cycles of 95°C 
for 45 s, 57°C for 45 s, 72°C for 1 min and a final extension 
of 10 min at 72°C. Ten microliters of each reaction were 
electrophoresed in a 1.5% agarose gel and stained with 
ethidium bromide. A 325-bp product was expected in DNA 
samples that contained the gE gene. As controls, PCR 
reactions for the gB coding gene (25) and the GFP gene 
(using the same pair of primers used for the construction 
of the pBoHV-1ΔgE plasmid) were performed.

Growth properties of recombinants in vitro

A virus growth experiment was performed to analyze 
the kinetics of replication of the BoHV-1ΔgE recombinant 
strain in comparison with the BoHV-1 SV56/90 parental 
strain. Cultures of MDBK cells were infected with each 
virus at a multiplicity of infection of 0.1 at 4°C for 1 h. 
Cultures were then incubated at 37°C with 5% CO2, 
harvested at different intervals and frozen at −80°C. The 
supernatants were titrated and the titers are reported as 
TCID50/mL (log10). To compare plaque size and morphol- 
ogy, MDBK cells were inoculated and adsorbed for 2 h 
with each virus, overlaid with 1.6% carboxymethylcellu- 
lose, incubated for 72 h, fixed with 10% buffered formalin 
and stained with 0.35% crystal violet.

Animal inoculation and serological testing

A total of thirteen 2- to 4-month-old male calves, 
negative for BoHV-1 antibodies, were inoculated with 
BoHV-1ΔgE#3 by the intramuscular route (im) at two 
different doses: 8 animals received a viral dose of 
107.3 TCID50/animal and 5 animals received 108.5 TCID50/ 
animal. These titers were selected as an average of the 
titers used by other authors (13,22,26). The number and 
age of the animals used for each inoculation followed the 
recommendations set out by the European Pharmacopoeia 
for tests of BoHV-1 live vaccines. Three calves were 
inoculated with the parental virus SV56/90 (107.5 TCID50/ 
animal). The virus neutralization (VN) antibody titers, 
expressed as the reciprocal of the highest dilution that 
prevents virus replication, were transformed into geo- 
metrical mean titers (GMT-log10) (27) for the calculation of 
the mean antibody titers of each group. After 42 days, sera 
were tested for virus neutralizing antibodies against BoHV-1 
by a VN assay, according to standard protocols (22).
To verify seroconversion to gE, serum samples were tested by a commercial anti-gE antibody ELISA test (Bovine Rhinotracheitis Virus gE Antibody Test, IDEXX, The Netherlands). Sera of calves previously inoculated with a gE-positive virus (28) were tested in parallel by a VN assay and an ELISA kit, as additional positive controls in both tests (Table 1).

All procedures of animal handling and experimentation were conducted under veterinary supervision and according to the recommendations of the Brazilian Committee of Animal Experimentation (law #6.638 of May 8, 1979). The experiment was approved by an Institutional Animal Ethics Committee, Universidade Federal de Santa Maria (approval #34/2014).

### Results

#### Selection of GFP-positive, gE-negative BoHV-1 recombinant viruses

Recombinant BoHV-1 viruses lacking the gE gene were constructed by homologous recombination between genomic DNA of a BoHV-1 strain (SV56/90) and a plasmid containing the gE flanking regions and the GFP gene replacing the gE coding region (Figure 1). After two attempts of co-transfection of MDBK cells with parental virus DNA, deletion plasmid and a bICP0 plasmid, and screening of approximately 5000 plaques, three fluorescent plaques were picked and amplified for further characterization. A representative fluorescent plaque is

---

**Table 1.** Serological response in calves inoculated with wild-type BoHV-1 or recombinant BoHV-1ΔgE#3.

| Animal                        | VN antibodies<sup>a</sup> | Anti-gE ELISA<sup>b</sup> |
|-------------------------------|--------------------------|--------------------------|
|                               | Day 0 | Day 42 pi<sup>c</sup> | Day 42 |
| BoHV-1ΔgE#3 10<sup>7.3</sup>TCD<sub>50</sub>/animal intramuscular |
| 101                           | <1<sup>d</sup> | 3<sup>e</sup> | – |
| 102                           | <1   | 3   | – |
| 104                           | <1   | 1   | – |
| 105                           | <1   | 2   | – |
| 106                           | <1   | 2   | – |
| 107                           | <1   | 3   | – |
| 108                           | <1   | 1   | – |
| 109                           | <1   | 1   | – |
| BoHV-1ΔgE#3 10<sup>8.5</sup>TCD<sub>50</sub>/animal intramuscular |
| 117                           | <1   | 2   | – |
| 127                           | <1   | 2   | – |
| 129                           | <1   | 3   | – |
| 132                           | <1   | 4   | – |
| 136                           | <1   | 2   | – |
| BoHV-1 SV56/90 (WT) 10<sup>7.3</sup>TCD<sub>50</sub>/animal intramuscular |
| 112                           | <1   | 1   | +<sup>g</sup> |
| 113                           | <1   | 2   | + |
| 114                           | <1   | 2   | + |
| BoHV-1 EVI123 10<sup>7.0</sup>TCD<sub>50</sub>/animal intranasal<sup>h</sup> |
| 179                           | <1   | 4   | + |
| 192                           | <1   | 4   | + |
| 349                           | <1   | 3   | + |
| 381                           | <1   | 4   | + |
| 4325                          | <1   | 2   | + |

<sup>a</sup> Virus neutralizing antibodies were measured by a virus neutralization (VN) assay as described in Material and Methods.

<sup>b</sup> Sera from 42 days post inoculation were subjected to a commercial anti-gE antibody ELISA test (Bovine Rhinotracheitis Virus gE Antibody Test, IDEXX, The Netherlands).

<sup>c</sup> pi: post inoculation.

<sup>d</sup> Sample negative in VN assay at its lower dilution (1:2).

<sup>e</sup> Results from the VN assay are reported as geometrical mean titers (GMT-log2).

<sup>f</sup> Samples negative for gE antibodies.

<sup>g</sup> Samples positive for gE antibodies.

<sup>h</sup> Animals from a previous study (28).
shown in Figure 2. Initially, viral clones derived from the three plaques were amplified and subjected to three rounds of plaque purification.

Then, DNA extracted from MDBK cells infected with each viral clone was subjected to PCR to detect the GFP and gE genes. One recombinant clone (clone #1) presented double bands in the gE PCR suggesting contamination with a gE-positive virus (data not shown), and was discarded. The remaining clones (#2 and #3) were further characterized. Figure 3 shows that these recombinants were indeed lacking the gE coding region (Figure 3A) and harboring the GFP marker gene (Figure 3C). Thus, the recombination strategy was successful and two pure BoHV-1 clones lacking the gE gene were obtained. These viral clones were further amplified for characterization and designated BoHV-1ΔgE#2 and BoHV-1ΔgE#3.

**In vitro characterization of BoHV-1ΔgE recombinants**

The *in vitro* properties of the recombinants BoHV-1ΔgE#2 and #3 were investigated and compared with the parental virus. The plaque size and morphology of the recombinants and parental viruses were monitored in MDBK cell monolayers. In general, the plaques produced by BoHV-1ΔgE#2 and #3 were smaller than those produced by the parental virus (Figure 4). The virus growth curve of the recombinants and parental viruses were assayed in MDBK cells and the results are shown in Figure 5. The results demonstrated that both BoHV-1ΔgE clones replicated with similar kinetics and to similar – even slightly higher – titers compared with the parental virus. Taken together, these results indicated that gE deletion had no major deleterious effects on the ability of the recombinant viruses to replicate efficiently in cell culture. This is a highly desirable property for a virus intended to be used as a vaccine strain.

**Behavior of the BoHV-1ΔgE recombinant in vivo: immunogenicity and serological differentiation in calves**

As the BoHV-1ΔgE recombinant viruses are intended for vaccine use, we next investigated their ability to replicate and to induce an immune response in calves. For this, two groups of calves (eight and five animals each) were inoculated *im* with the BoHV-1ΔgE #3 virus in two doses (10^{7.3}TCID_{50} and 10^{8.5}TCID_{50} per animal) and tested for VN antibodies 42 days after inoculation. All calves inoculated with the BoHV-1ΔgE #3 seroconverted, developing VN titers from 2 to 16 at 42 days post inoculation. Similar titers were observed in three calves inoculated with the parental virus (Table 1). These data indicated that the recombinant BoHV-1ΔgE#3 is able to replicate efficiently in calves following *im* administration and induce a VN response in levels comparable with that induced by the parental virus.

We next investigated the ability of the recombinant BoHV-1ΔgE#3 to induce a serological response that could be differentiated from the immune response induced by a gE positive virus. For comparison, we used serum samples collected from calves inoculated with a wild-type BoHV-1 (28). Serum samples collected at 42 days post inoculation were tested by an anti-gE ELISA kit. As shown in Table 1, all calves immunized with the recombinant BoHV-1ΔgE#3 remained negative in the gE ELISA, contrasting with the...
animals immunized with a gE-positive virus. These data demonstrate that the serological response induced by the recombinant BoHV-1ΔgE can be differentiated from that induced by the wild type virus by an anti-gE ELISA test.

Discussion

A recombinant BoHV-1 with a gE gene deletion (BoHV-1ΔgE) was constructed with the primary goal of being used as a vaccine strain. Following a long-term trend observed in many European and North American countries, Brazil has also embarked on the development of antigenically marked BoHV-1 strains for vaccine use (19-21). A gE negative BoHV-1 strain constructed from a Brazilian isolate has proven to be safe, immunogenic and allows for serological differentiation (19,21,22). More recently, a double deletion (thymidine kinase/gE) BoHV-5 recombinant was constructed and evaluated positively as a candidate vaccine strain (14,15,28-30). Although BoHV-1 and BoHV-5 are antigenically similar, and vaccines based on either virus are expected to confer cross-protection (28), no vaccine containing gene-deleted BoHV-1 or BoHV-5 is yet available in Brazil. Thus, to address this, we constructed a gE-deleted recombinant BoHV-1 strain. We chose a genital Brazilian BoHV-1 strain (SV56/90) as the parental virus for the following reasons: 1) SV56/90 is a well characterized BoHV-1 strain; 2) it replicates to high titers in vitro, a desirable property for a vaccine strain; 3) it is highly immunogenic in cattle; 4) genital and respiratory BoHV-1 are antigenically similar (sometimes indistinguishable) and are highly cross-reactive serologically. Additionally, strain SV56/90 has been extensively characterized at biological, antigenic and molecular levels (31-33).

The strategy of complete gE gene deletion has also been used to construct recombinant BoHV-1ΔgE virus by other authors (17,20). Other authors chose to perform a partial deletion of the gE gene, keeping the portion next to the Us9 gene, but no significant differences were observed compared with full deletion (13,26). Using both of these strategies, the possibility of serological differentiation by an ELISA test was maintained.

The homologous DNA recombination that results in the generation of recombinant genomes is a rare event and, as a consequence, the selection of recombinant viruses resulting from this event can be laborious work. The incorporation of the GFP gene into the BoHV-1ΔgE genome was an easy means to identify and recover gE-deleted recombinant viruses after transfection and also helped to monitor virus purity after plaque purification (13). The bICP0-expressing plasmid was pivotal for the success of the recombination protocol, since bICP0 is an essential trans-activator of BoHV-1 immediate early genes (34).

In vitro characterization of the two BoHV-1ΔgE clones showed that their ability to replicate in cell culture was not adversely affected by gE deletion, as they replicated to titers comparable with those of the parental virus (Figure 1). Indeed, previous studies have shown that
BoHV-1ΔgE recombinants are able to replicate in vitro to similar titers as the parental virus (13,14). The ability to replicate to high titers in cell culture is an obvious advantage of virus strains intended to be used for vaccine production. However, the recombinants produced smaller plaques than the parental virus, a property already observed in gE-defective BoHV-1 (7,13) and BoHV-5 viruses (14). This phenotype is probably associated with the fact that gE – complexed with gI – is involved in cell-to-cell spread in vitro (35,36). The choice of gE as a target for deletion was also based upon the role of this glycoprotein in anterograde transport of the virus from nerve ganglia to the nose after reactivation of latency (37). Thus, gE-deleted viruses are not transported efficiently back to the nose and, consequently, they are not re-excreted and transmitted upon reactivation (38).

To determine whether the BoHV-1ΔgE virus strain would retain its replication ability and immunogenicity in vivo, groups of calves were inoculated im with the virus and the serological response was measured at 42 days post-inoculation. The serological response of the animal inoculated with the BoHV-1ΔgE virus was similar in magnitude to that induced in animals inoculated with wild-type virus. In general, the antibody titers observed here were similar to those reported in previous studies (13,26) when live gE-deleted BoHV-1 was inoculated by the im route, even when younger animals were used. These results showed that the gE-deleted virus retained its immunogenicity and, thus, has the potential to be used as a vaccine strain. Early studies have shown that gE-deleted herpesviruses generate similar or slightly lower serological responses when compared with wild-type viruses (13) or vaccines strains (7,12).

In addition to the immunogenic potential, an important feature of a gene-deleted vaccine is the possibility of differentiation of vaccinated from naturally infected animals (6). In our testing, the animals inoculated with the recombinant BoHV-1ΔgE mounted a serological response that, at 42 days post inoculation, could be differentiated from that mounted by animals inoculated with gE-positive viruses. Although based on a small number of animals, these results demonstrated the differential properties of this candidate vaccine strain.

The in vivo data presented here are still preliminary and require further experimentation before the recombinant strain is considered adequate for vaccine use. These studies are underway and include: 1) safety and immunogenicity tests in different animal categories (including young calves and pregnant cows); 2) immunogenicity tests using inactivated virus, since the licensing of such vaccines is more feasible in Brazil than with live vaccines; 3) vaccination-challenge experiments to investigate the ability of the recombinant virus to confer protection upon challenge; and 4) an experiment to investigate whether the recombinant virus is safe for use in pregnant cows.

An antigenically marked BoHV-1 vaccine to be used in Brazilian cattle would be an important contribution in the control of this infection in a number of ways: 1) control and eradication of BoHV-1 have been achieved in some European countries using a similar strategy; 2) Brazil and other South American countries have long been planning to use DIVA vaccines against bovine herpesviruses; 3) a commercial anti-gE ELISA kit for differentiation of vaccinated from naturally infected animals is already available. For these reasons, and considering the properties demonstrated by recombinant BoHV-1ΔgE in vitro and in vivo, we consider that this strain is suitable to be included in either modified-live or inactivated vaccine formulations for the control of BoHV-1 infection in Brazil.

Acknowledgments

This article is part of the doctoral thesis of M. Weiss, who is the recipient of a doctoral scholarship from CNPq (#142148/2011-3). E.F. Flores and R. Weiblen are recipients of CNPq scholarships. The research was supported by PRONEX, FAPERGS, and CNPq.

References

1. Kahrs RF. Infectious bovine rhinotracheitis and pustular vulvovaginitis. In: Kahrs RF (Editor), Viral diseases of cattle. 2nd edn. Ames: Iowa State University; 2001. p 159-170.
2. Muyldems B, Thiry J, Kirten P, Schynts F, Thiry E. Bovine herpesvirus 1 infection and infectious bovine rhinotracheitis. Vet Res 2007; 38: 181-209, doi: 10.1051/vetres:2006059.
3. Melo CS, Lobato ZIP, Camargos MF, Souza GN, Martins NRS, Leite RC. Distribution of antibodies to bovine herpesvirus 1 in cattle herds. Arq Bras Med Vet Zootec 2002; 54: 575-580, doi: 10.1590/S0102-0352002000600003.
4. Dias JA, Affierl AA, Medici KC, Freitas JC, Ferreira JS, Muller EE. Risk factors for bovine herpesvirus 1 infection in cattle herds in the West region of Paraná State. Pesquisa Vet Brasil 2008; 28: 161-168.
5. Roizmann B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, Studdert MJ. The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol 1992; 123: 425-448, doi: 10.1007/BF01317276.
6. van Oirschot JT, Kaashoek MJ, Maris-Veldhuis MA, Rijswijk FA. Strains of bovine herpesvirus 1 that do not express an epitope on glycoprotein E in cell culture still induce antibodies that can be detected in a gE-blocking ELISA. Vet Microbiol 1999; 65: 103-113, doi: 10.1016/S0378-1135(98)00295-8.
7. Kaashoeck MJ, Moerman A, Madic J, Rijswijk FA, Quak J, Gielkens AL, et al. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an
850 M. Weiss et al.

10. Muylkens B, Meurens F, Schyns F, Farnir F, Pourchet A, Pastoret PP, et al. Virulence, immunogenicity and reactiva-
tion of bovine herpesvirus 1 mutants with a deletion in the
G C, gG, gl, gE, or in both the gl and gE gene. Vaccine 1998;
16: 802-809, doi: 10.1016/S0264-410X(97)00269-7.

11. Kaashoek MJ, Moerman A, Madic J, Weerdmeester K, Maris-
Veldhuis M, Rijsewijk FA, et al. An inactivated vaccine based
on a glycoprotein E-negative strain of bovine herpesvirus 1 induces
protective immunity and allows serological differentiation.
Vaccine 1995; 13: 342-346, doi: 10.1016/S0264-410X(95)00254-8.

12. Chowdhury SI, Ross CS, Lee BJ, Hall V, Chu HJ.
Construction and characterization of a glycoprotein E
gene-deleted bovine herpesvirus type 1 recombinant.
Am J Vet Res 1999; 60: 227-232.

13. Brum MC, Weiblen R, Flores EF. Construction and growth properties of bovine herpesvirus type 5 recombi-
nants defective in the glycoprotein E or thymidine kinase gene
or both. Braz J Med Biol Res 2010; 43: 217-224, doi:
10.1590/S0100-736X2009075000008.

14. Robinson KE, Meers J, Gravel JL, McCarthy FM, Mahony
TJ. The essential and non-essential genes of BoHV-1 recombi-
nants defective in the glycoprotein E or thymidine kinase gene
or both. J Gen Virol 2008; 89: 2851-2863, doi:
10.1099/vir.0.02501-0.

15. van Engelenburg FA, Kaashoek MJ, Rijsjiewijk FA, van den
Burg L, Moerman A, Gielkens AL, et al. A glycoprotein E
deletion mutant of bovine herpesvirus 1 is avirulent in
calves. J Gen Virol 1994; 75 (Part 9): 2311-2318, doi:
10.1099/vir.0.02501-0.

16. van Oirschot JT. Diva vaccines that reduce virus transmis-
sion. J Biotechnol 1999; 73: 195-205, doi: 10.1016/S0168-1656(99)00121-2.

17. Franco AC, Spilki FR, Esteves PA, de Lima M, Weiblen R,
Flores EF, et al. A Brazilian glycoprotein E-negative bovine
herpesvirus type 1.2a (BHV-1.2a) mutant is attenuated for
cattle and induces protection against wild-type virus
challenge. Pesquisa Vet Brasil 2002; 22: 135-140.

18. Spilki FR, Silva AD, Batista HBCR, Oliveira AP, Winkelmann
E, Franco AC, et al. Field evaluation of safety during
gestation and horizontal spread of a recombinant differential
bovine herpesvirus 1 (BoHV-1) vaccine. Pesquisa Vet Brasil
2005; 25: 54-58, doi: 10.1590/S0100-736X2005000100010.

19. Weiss M, Vogel FSF, Martins M, Weiblen R, Rohe PM,
Franco AC, et al. Genital immunization of heifers with a
glycoprotein E-deleted, recombinant bovine herpesvirus 1
strain confers protection upon challenge with a virulent
isolate. Pesquisa Vet Brasil 2010; 30: 42-50, doi: 10.1590/
S0100-736X2010000100007.

20. Weiss M, Kreutz LC, Canabarbo TF, Schuch LF, Rebello
MC. Isolation of bovine herpesvirus 1 from prepulmonary
semen and semen of bulls with balanoposthitis. Vet Diagn
Invest 1992; 4: 341-343, doi: 10.1177/0476387920400321.

21. Inman M, Zhang Y, Geiser V, Jones C. The zinc ring finger in
the bICp0 protein encoded by bovine herpesvirus-1 mediates
toxicity and activates productive infection. J Gen Virol 2001;
82: 483-492.

22. Die I. G. Almeida SR, Brum MC, Demergrini RM, Weiblen R,
Flores EF. Acute and latent infection by bovine herpesvirus
5 type in experimentally infected goats. Vet Microbiol 2007;
121: 257-267, doi: 10.1016/j.vetmic.2006.12.019.

23. Roemer SA, Pantel M, Quattrocchi V, Del Medico ZP,
Zamorano P, Blanco Viera J, et al. Protection induced by a
glycoprotein E-deleted bovine herpesvirus type 1 marker strain
used either as an inactivated or live attenuated vaccine in
cattle. BMC Vet Res 2014; 10: 8, doi: 10.1186/1746-6148-10-8.

24. Anziliero D, Santos CM, Brum MC, Weiblen R, Flores EF.
A recombinant bovine herpesvirus 5 defective in thymidine
kinase and glycoprotein E is immunogenic for calves and
confers protection upon homologous challenge and BoHV-1 challenge. Vet Microbiol 2011; 154: 14-22, doi:
10.1016/j.vetmic.2011.03.019.

25. Anziliero D, Santos CM, Brum MC, Weiblen R, Flores EF.
A recombinant bovine herpesvirus 5 defective in thymidine
kinase and glycoprotein E is attenuated and immunogenic for
calves. Pesquisa Vet Brasil 2011; 31: 23-30, doi: 10.1590/S0100-736X2011001000004.

26. Santos CM, Anziliero D, Bauermann FV, Cardozo L,
Bernardes LM, Brum MCS, et al. A recombinant bovine
herpesvirus 5 defective in thymidine kinase and glycoprotein E
is attenuated and immunogenic for calves. Pesquisa Vet Brasil
2011; 31: 23-30, doi: 10.1590/S0100-736X2011001000004.

27. Silva MS, Brum MC, Loreto EL, Weiblen R, Flores EF.
Molecular and antigenic characterization of Brazilian bovine
herpesvirus type 1 isolates recovered from the brain of calf
with neurological disease. Virus Res 2007; 129: 191-199,
doi: 10.1016/j.virusres.2007.07.014.

28. Silva M, Brum MCS, Weiblen R, Flores EF. Identification
and differentiation of herpesvirus types 1 and 5 isolated from
clinical samples in central-southern Brazil, Argentina and
Uruguay (1987-2006). Pesquisa Vet Brasil 2007; 27: 403-408.

29. Traesel CK, Sa e Silva M, Weiss M, Spilki FR, Weiblen R,
Flores EF. Genetic diversity of 3’ region of glycoprotein D
gene of bovine herpesvirus 1 and 5. Virus Genes 2014; 48:
438-447, doi: 10.1007/s11262-014-1040-5.

30. Geiser V, Zhang Y, Jones C. Analysis of a bovine
herpesvirus 1 recombinant virus that does not express the
bICP0 protein. J Gen Virol 2005; 86: 1987-1996, doi: 10.1099/vir.0.80921-0.

35. Dingwell KS, Johnson DC. The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions. J Virol 1998; 72: 8933-8942.

36. Zsak L, Zuckermann F, Sugg N, Ben-Porat T. Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission. J Virol 1992; 66: 2316-2325.

37. Mars MH, de Jong MC, van Oirschot JT. A gE-negative bovine herpesvirus 1 vaccine strain is not re-excreted nor transmitted in an experimental cattle population after corticosteroid treatments. Vaccine 2000; 18: 1975-1981, doi: 10.1016/S0264-410X(99)00536-8.

38. Brum MC, Coats C, Sangena RB, Doster A, Jones C, Chowdhury SI. Bovine herpesvirus type 1 (BoHV-1) anterograde neuronal transport from trigeminal ganglia to nose and eye requires glycoprotein E. J Neurovirol 2009; 15: 196-201, doi: 10.1080/13550280802549605.